The decrease in net loss for the quarter included a reduction in non cash Stock based compensation and decrease in total interest expense, partially offset by a $1,400,000 non cash charge Due to the change in fair value of warrant liabilities associated with warrant certificates tied to the anticipated drawdown of the $10,000,000 tranche B from the Perceptive Advisors term loan facility in the 4th quarter. To provide better clarity of our progress on our path to profitability, we are now reporting adjusted EBITDA, which excludes certain non cash items and COVID-nineteen testing revenue and direct costs and expenses. Adjusted EBITDA for the Q3 2023 was a loss of $5,400,000 compared to a loss of $9,100,000 For both the Q3 2022 and Q2 2023, a 40% improvement over both periods and notably a 60% improvement over the Q1 of 2023. The improvement in adjusted EBITDA in the quarter demonstrates our focus on actively managing our operating expenses, our success in improving gross margins and driving growth in the top line revenue. We ended the quarter with $19,800,000 in unrestricted cash and cash equivalents as compared to $17,400,000 in unrestricted cash and cash At the end of the second quarter, an increase of $2,400,000 which included the scheduled milestone payment $3,300,000 paid in July 2023 to Integrated Diagnostics, changes in working capital And also includes $5,300,000 in tenant improvement dollars, which are now exhausted, offset by $5,800,000 in investment in the new facility.